Resistant Hypertension – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Resistant Hypertension – Drugs In Development, 2024 report and make more profitable business decisions.
Resistant hypertension is defined as hypertension that is poorly responsive to treatment and requires the use of multiple medications to achieve acceptable blood pressure ranges. It may be a consequence of secondary hypertension or have no identifiable cause. Resistant hypertension substantially increases the risk of heart attack, stroke and kidney failure
The Resistant Hypertension drugs in development market research report provide comprehensive information on the therapeutics under development for Resistant Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Resistant Hypertension | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 15 molecules, with 15 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Resistant Hypertension therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Resistant Hypertension pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Resistant Hypertension treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Adepthera LLCAntlia Bioscience Inc
CinCor Pharma Inc
Daiichi Sankyo Co Ltd
Idorsia Pharmaceutical Ltd
Ionis Pharmaceuticals Inc
Ji Xing Pharmaceuticals Ltd
Mineralys Therapeutics Inc
Novartis AG
Panorama Research Institute
Sarfez Pharmaceuticals Inc
Target Medicals
Zumbro Discovery Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Resistant Hypertension reports